Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye drops could keep Kids' vision from getting worse

NCT ID NCT07626892

Disease control Sponsor: Khyber Medical College, Peshawar Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested three low doses of atropine eye drops (0.01%, 0.03%, and 0.05%) in 95 children aged 6–18 with nearsightedness. The goal was to see which dose best slowed the worsening of myopia with the fewest side effects. Over 18 months, the 0.05% dose worked best at controlling vision changes, while all doses were generally well-tolerated.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
atropine eye drops (low concentrations 0.01%, 0.03%, 0.05%)
What this could lead to
If confirmed, this could give doctors a safe, effective way to slow worsening nearsightedness in children, reducing their risk of serious eye problems later in life.
What could go wrong
This was a small, single-country study. The results may not apply to all children, and long-term safety beyond 18 months is not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

95 people

The number who actually took part.

Started

Jun 2024

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children aged 6-18 years. * SER between -1.00 and -6.00 diopters. Exclusion Criteria: * History of ocular surgery or trauma. * Use of other myopia control interventions in the last 6 months. * Allergies to atropine.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atropine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

degenerative myopia myopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atropine Myopia progression

Contacts and locations

Locations

  • Khyber Teaching Hospital

    Peshawar, KPK, 25000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.